EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with limited therapeutic strategies.
• Epidermal growth factor receptor (EGFR) and receptor tyrosine kinase erbB2 are implicated in MPNST development.
• Understanding genetic alterations and protein expression is crucial for identifying novel treatment targets.

Purpose of the Study:

• To systematically investigate EGFR and erbB2 as potential therapeutic targets in MPNSTs.
• To analyze genetic alterations, including gene dosage and loss of tumor suppressor genes, in a panel of MPNSTs.
• To evaluate the efficacy of EGFR and erbB2 targeted drugs in MPNST cell lines.

Main Methods:

• Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization were used to assess gene dosage.
• Analysis included 37 MPNST samples and matched neurofibromas.
• MPNST cell lines were treated with erlotinib and trastuzumab to assess drug effects on proliferation and signaling pathways.

Main Results:

• Increased EGFR gene dosage was observed in 28% of MPNSTs.
• Frequent loss or reduction of tumor suppressor genes (PTEN, CDKN2A, TP53) was detected; CDKN2A loss correlated with metastasis.
• EGFR and erbB2 protein expression was common, with EGFR expression linked to gene dosage. Erlotinib inhibited MPNST cell proliferation dose-dependently.

Conclusions:

• EGFR and erbB2 are frequently altered and expressed in MPNSTs, representing promising therapeutic targets.
• EGFR signaling is active in MPNSTs, and inhibition with erlotinib shows anti-proliferative effects.
• Targeted therapy against EGFR may offer a new treatment avenue for MPNST patients.